Federal study would test all adults in a community for AIDS

The New York Times reports that "Federal health officials are preparing a plan to study a bold new strategy to stop the spread of the AIDS virus: routinely testing virtually every adult in a community, and promptly treating those found to be infected. The strategy is called 'test and treat,' and officials say the two sites for the three-year study will be the District of Columbia and the Bronx — locales with some of the nation's highest rates of infection with human immunodeficiency virus."

Officials say this is "just a first step" and that the "goal is not to measure whether 'test and treat' actually works to slow an epidemic, but whether such a strategy can even be carried out, given the many barriers to being tested and getting medical care." Dr. Shannon L. Hader, director of the HIV/AIDS administration in D.C.'s Department of Health, said in the article that "as many as 5 percent of the adults in the District of Columbia are infected — a rate ... comparable with those in West Africa — and one-third to one-half do not even know they harbor the virus. ... In 2006, only about half of Washington residents who had a new diagnosis of H.I.V. saw a doctor about the problem within six months" (Okie, 10/27).

Kaiser Health NewsThis article was reprinted from khn.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Semaglutide reduced mortality in obese patients by lowering infection-related deaths during COVID-19 pandemic